Table 3 Comparison of Graves’ disease patients who experienced relapse after ATDs discontinuation versus patients who did not experience relapse
From: Efficacy of Anti-Thyroid Medications in Patients with Graves’ Disease
Variable | Relapse (n = 35) | No relapse (n = 68) | P-value |
|---|---|---|---|
Age (years), n, [Median (IQR)] | 35,[38.0( 33.00, 51.00)] | 68,[39( 34.00, 49.50)] | 0.826^ |
Free T3 upon diagnosis(pmol/l), n, [Median (IQR)] | 35,[9.1( 5.80, 15.70)] | 68,[9.4( 7.05, 16.60)] | 0.526^ |
Free T4 upon diagnosis(pmol/l), n, [Mean (SD)] | 35,[26.7 ( 8.21 )] | 68,[25.4 ( 9.31 )] | 0.495* |
TSH receptor antibodies level up on diagnosis(IU/l), n, [Median (IQR)] | 32,[5.0( 3.70, 10.90)] | 61,[5.1( 2.50, 10.30)] | 0.454^ |
Thyroid uptake on 99mTc-pertechnetate scan (%),n, [Median (IQR)] | 30,[10.3( 5.19, 16.81)] | 49,[6.0( 3.09, 12.38)] | 0.030^ |
BMI (Kg/m2), n, Mean (SD) | 35,[27.8 ( 6.38 )] | 68,[29.3 ( 5.58 ) | 0.215* |
Duration of ATDs treatment (months), n, [Median (IQR)] | 35,[40.0( 29.00, 58.00)] | 68,[25.0( 19.00, 32.50)] | < 0.0001^ |
Female patients, n (%) | 30 ( 85.7 ) | 54 ( 79.4 ) | 0.435** |
Male patients, n (%) | 5 ( 14.3 ) | 14 ( 20.6 ) | 0.435** |
Mild ophthalmopathy, n (%) | 29 ( 87.9 ) | 52 ( 82.5 ) | 0.494** |
Moderate ophthalmopathy, n (%) | 4 ( 12.1 ) | 11 ( 17.5 ) | 0.494** |